OTCMKTS:CYDY - CytoDyn Stock Price, Price Target & More

$0.51 0.00 (0.00 %)
(As of 04/23/2018 09:26 AM ET)
Previous Close$0.51
Today's Range$0.50 - $0.5290
52-Week Range$0.4551 - $0.8360
Volume146,300 shs
Average Volume286,211 shs
Market Capitalization$108.16 million
P/E Ratio-2.68
Dividend YieldN/A
Beta0.64

About CytoDyn (OTCMKTS:CYDY)

CytoDyn logoCytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company is based in Vancouver, Washington.

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:CYDY
CUSIPN/A
Phone360-980-8524

Debt

Debt-to-Equity RatioN/A
Current Ratio0.53%
Quick Ratio0.53%

Price-To-Earnings

Trailing P/E Ratio-2.68
Forward P/E Ratio-1.96
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.01) per share
Price / Book-51.00

Profitability

EPS (Most Recent Fiscal Year)($0.19)
Net Income$-25,760,000.00
Net MarginsN/A
Return on Equity-10,003.02%
Return on Assets-654.43%

Miscellaneous

Employees146
Outstanding Shares212,080,000

How to Become a New Pot Stock Millionaire

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn (OTCMKTS:CYDY) announced its earnings results on Tuesday, October, 10th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for CytoDyn.

What price target have analysts set for CYDY?

1 brokerages have issued 1 year target prices for CytoDyn's shares. Their forecasts range from $2.00 to $2.00. On average, they expect CytoDyn's share price to reach $2.00 in the next year. View Analyst Ratings for CytoDyn.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:
  • Mr. Anthony D. Caracciolo, Exec. Chairman (Age 63)
  • Dr. Nader Z. Pourhassan Ph.D., Pres, CEO & Director (Age 55)
  • Dr. Denis R. Burger, Vice Chairman and Chief Science Officer (Age 74)
  • Mr. Michael D. Mulholland CPA, CFO, Treasurer & Corp. Sec. (Age 66)

Has CytoDyn been receiving favorable news coverage?

Media headlines about CYDY stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytoDyn earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $0.51.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $108.16 million. The biotechnology company earns $-25,760,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. CytoDyn employs 146 workers across the globe.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (CYDY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytoDyn (OTCMKTS:CYDY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for CytoDyn in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 292.16%. The high price target for CYDY is $2.00 and the low price target for CYDY is $2.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00$2.00$2.00
Price Target Upside: 292.16% upside189.86% upside233.33% upside179.04% upside

CytoDyn (OTCMKTS:CYDY) Consensus Price Target History

Price Target History for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS:CYDY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/9/2018HC WainwrightSet Price TargetBuy$2.00View Rating Details
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60View Rating Details
(Data available from 4/23/2016 forward)

Earnings

CytoDyn (OTCMKTS:CYDY) Earnings History and Estimates Chart

Earnings by Quarter for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS:CYDY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.21 EPS

CytoDyn (OTCMKTS CYDY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
10/10/2017Q1 2018($0.05)($0.08)ViewN/AView Earnings Details
7/20/2017Q4 2017($0.05)ViewN/AView Earnings Details
4/13/2017Q3 2017($0.04)($0.06)ViewN/AView Earnings Details
1/13/2017Q2 2017($0.04)($0.05)ViewN/AView Earnings Details
10/12/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
7/19/2016Q4 2016($0.05)ViewN/AView Earnings Details
4/13/2016Q3 2016($0.05)ViewN/AView Earnings Details
1/11/2016Q2 2016($0.06)ViewN/AView Earnings Details
10/9/2015Q1 2016($0.12)ViewN/AView Earnings Details
7/10/2015Q4 2015($0.24)ViewN/AView Earnings Details
4/10/2015Q3 2015($0.05)ViewN/AView Earnings Details
1/12/2015Q2 2015($0.09)ViewN/AView Earnings Details
10/10/2014Q1 2015($0.06)ViewN/AView Earnings Details
7/18/2014Q4 2014($0.05)ViewN/AView Earnings Details
4/11/2014Q3 2014($0.06)ViewN/AView Earnings Details
1/13/2014Q2 2014($0.08)ViewN/AView Earnings Details
10/15/2013Q1 2014($0.08)ViewN/AView Earnings Details
8/29/2013Q4 2013($0.08)ViewN/AView Earnings Details
4/12/2013Q3 2013($0.08)ViewN/AView Earnings Details
1/14/2013Q2 2013($0.06)ViewN/AView Earnings Details
10/9/2012Q1 2013($0.10)ViewN/AView Earnings Details
8/22/2012Q4 2012($0.13)ViewN/AView Earnings Details
4/16/2012Q3 2012($0.06)ViewN/AView Earnings Details
1/17/2012Q2 2012($0.07)ViewN/AView Earnings Details
11/22/2011Q1 2012($0.05)ViewN/AView Earnings Details
11/3/2011Q4 2011($0.05)ViewN/AView Earnings Details
10/7/2011Q3 2011($0.05)ViewN/AView Earnings Details
1/14/2011Q2 2011($0.05)ViewN/AView Earnings Details
12/14/2010Q1 2011($0.03)ViewN/AView Earnings Details
12/3/2010Q4 2010($0.42)ViewN/AView Earnings Details
10/25/2010Q3 2010($0.04)ViewN/AView Earnings Details
9/28/2010Q2 2010($0.04)ViewN/AView Earnings Details
8/31/2010Q1 2010($0.02)ViewN/AView Earnings Details
6/23/2010Q3 2009($0.02)ViewN/AView Earnings Details
6/3/2010Q2 2009($0.05)ViewN/AView Earnings Details
5/20/2010Q1 2009($0.04)ViewN/AView Earnings Details
3/12/2010Q4 2008($0.04)ViewN/AView Earnings Details
12/1/2009Q3 2008($0.02)ViewN/AView Earnings Details
9/25/2009Q1 2008($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CytoDyn (OTCMKTS:CYDY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CytoDyn (OTCMKTS CYDY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 0.11%
Insider Trading History for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS CYDY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/21/2016Nader PourhassanInsiderBuy15,000$0.66$9,900.0060,056View SEC Filing  
10/17/2016Michael D MulhollandCFOBuy11,000$0.66$7,260.0037,043View SEC Filing  
10/30/2014Anthony CaraccioloDirectorBuy26,000$0.72$18,720.00View SEC Filing  
10/15/2014Michael D MulhollandCFOBuy2,500$0.79$1,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytoDyn (OTCMKTS CYDY) News Headlines

Source:
DateHeadline
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM ...CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM ...
globenewswire.com - April 12 at 4:28 PM
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018
finance.yahoo.com - April 12 at 10:17 AM
Form 8-K CytoDyn Inc. For: Apr 11Form 8-K CytoDyn Inc. For: Apr 11
www.streetinsider.com - April 11 at 10:05 AM
HC Wainwright Analysts Give CytoDyn (CYDY) a $2.00 Price TargetHC Wainwright Analysts Give CytoDyn (CYDY) a $2.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM
CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological DisordersCytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders
finance.yahoo.com - March 29 at 9:49 AM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)Glancy Prongay & Murray LLP Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)
finance.yahoo.com - March 27 at 4:25 PM
CytoDyn And HIV Therapy: CCR5 Antagonist Is An Old Drug Made NewCytoDyn And HIV Therapy: CCR5 Antagonist Is An Old Drug Made New
seekingalpha.com - March 25 at 9:39 AM
HC Wainwright Reiterates "$2.00" Price Target for CytoDyn (CYDY)HC Wainwright Reiterates "$2.00" Price Target for CytoDyn (CYDY)
www.americanbankingnews.com - March 9 at 8:02 PM
CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV InfectionCytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection
finance.yahoo.com - February 20 at 9:04 AM
CytoDyn (CYDY) Given a $2.00 Price Target at HC WainwrightCytoDyn (CYDY) Given a $2.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 18 at 7:00 PM
CytoDyn (CYDY) Cut to Sell at Zacks Investment ResearchCytoDyn (CYDY) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - February 12 at 10:12 PM
CytoDyn (CYDY) Raised to "Hold" at Zacks Investment ResearchCytoDyn (CYDY) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 9:28 PM
CytoDyn (CYDY) Lowered to Sell at Zacks Investment ResearchCytoDyn (CYDY) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 31 at 10:24 PM
CytoDyn (CYDY) Receives Buy Rating from HC WainwrightCytoDyn (CYDY) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - December 8 at 7:38 PM
HC Wainwright Reaffirms Buy Rating for CytoDyn (CYDY)HC Wainwright Reaffirms Buy Rating for CytoDyn (CYDY)
www.americanbankingnews.com - November 29 at 12:22 PM
Cytodyn Is Worth A Look Before Phase 3 HIV Data - Seeking AlphaCytodyn Is Worth A Look Before Phase 3 HIV Data - Seeking Alpha
seekingalpha.com - November 21 at 4:45 AM
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell TransplantationCytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
finance.yahoo.com - November 14 at 6:10 PM
CytoDyns Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)CytoDyn's Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)
globenewswire.com - November 17 at 8:48 AM
CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)
globenewswire.com - October 24 at 9:45 AM
SeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.caSeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.ca
www.baystreet.ca - October 21 at 4:34 PM
CYTODYN INC. Files SEC form 10-Q, Quarterly ReportCYTODYN INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - October 12 at 4:47 PM
Coherus Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - NasdaqCoherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - Nasdaq
www.nasdaq.com - October 7 at 4:28 PM
CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)
globenewswire.com - October 6 at 10:04 AM
CytoDyn inks $9M direct equity offering; shares off 16% - Seeking AlphaCytoDyn inks $9M direct equity offering; shares off 16% - Seeking Alpha
seekingalpha.com - September 12 at 4:21 PM
CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - September 12 at 4:21 PM
CYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ECYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
biz.yahoo.com - September 12 at 9:25 AM
CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)
globenewswire.com - September 8 at 8:20 AM

SEC Filings

CytoDyn (OTCMKTS:CYDY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

CytoDyn (OTCMKTS CYDY) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.